Immucell (ICCC) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $10.56, -1.77% vs the prior close of $10.75.
- Volume 9.90K shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ICCC dips 1.8% to $10.56. Closed at $10.56, -1.77% vs the prior close of $10.75. Day range $10.45–$10.89, opened at $10.45.
ICCC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ICCC dips 1.8% to $10.56
- Closed at $10.56, -1.77% vs the prior close of $10.75. Day range $10.45–$10.89, opened at $10.45.
- Volume was 9.90K shares, 0.5x its 50-day average of 20.85K — lighter than usual.
- Price is +5.0% vs its 50-day average ($10.06) and +22.2% vs its 200-day average ($8.64).
- 52-week range $4.52–$12.10; today's close sits at 80% of that range, 12.7% below the 52-week high.
Oct 14, 2026 — ICCC dips 0.4% to $10.75
- Closed at $10.75, -0.37% vs the prior close of $10.79. Day range $10.50–$10.80, opened at $10.80.
- Volume was 9.40K shares, 0.4x its 50-day average of 21.22K — lighter than usual.
- Price is +6.8% vs its 50-day average ($10.06) and +24.8% vs its 200-day average ($8.62).
- 52-week range $4.52–$12.10; today's close sits at 82% of that range, 11.2% below the 52-week high.
Oct 13, 2026 — ICCC jumps 12.4% to $10.79, a 1-month high on 2.4x normal volume
- Closed at $10.79, +12.40% vs the prior close of $9.60. Day range $10.15–$10.80, opened at $10.79.
- Volume was 50.30K shares, 2.4x its 50-day average of 20.54K — unusually heavy trading.
- Price is +7.2% vs its 50-day average ($10.07) and +25.6% vs its 200-day average ($8.59).
- 52-week range $4.52–$12.10; today's close sits at 83% of that range, 10.8% below the 52-week high.
- SEC filings that day: 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 12, 2026 — ICCC dips 2.0% to $9.60
- Closed at $9.60, -2.04% vs the prior close of $9.80. Day range $9.60–$9.80, opened at $9.75.
- Volume was 11.20K shares, 0.5x its 50-day average of 20.52K — lighter than usual.
- Price is -4.7% vs its 50-day average ($10.07) and +12.0% vs its 200-day average ($8.57).
- 52-week range $4.52–$12.10; today's close sits at 67% of that range, 20.7% below the 52-week high.
Oct 9, 2026 — ICCC rises 0.5% to $9.80
- Closed at $9.80, +0.51% vs the prior close of $9.75. Day range $9.65–$9.80, opened at $9.75.
- Volume was 1.90K shares, 0.1x its 50-day average of 20.98K — lighter than usual.
- Price is -3.0% vs its 50-day average ($10.10) and +14.6% vs its 200-day average ($8.55).
- 52-week range $4.52–$12.10; today's close sits at 70% of that range, 19.0% below the 52-week high.
Oct 8, 2026 — ICCC rises 0.6% to $9.75
- Closed at $9.75, +0.62% vs the prior close of $9.69. Day range $9.65–$9.85, opened at $9.74.
- Volume was 5.10K shares, 0.2x its 50-day average of 21.38K — lighter than usual.
- Price is -3.8% vs its 50-day average ($10.13) and +14.3% vs its 200-day average ($8.53).
- 52-week range $4.52–$12.10; today's close sits at 69% of that range, 19.4% below the 52-week high.
Oct 7, 2026 — ICCC dips 2.8% to $9.69
- Closed at $9.69, -2.81% vs the prior close of $9.97. Day range $9.69–$9.99, opened at $9.96.
- Volume was 5.20K shares, 0.2x its 50-day average of 21.45K — lighter than usual.
- Price is -4.6% vs its 50-day average ($10.16) and +13.9% vs its 200-day average ($8.51).
- 52-week range $4.52–$12.10; today's close sits at 68% of that range, 19.9% below the 52-week high.
Oct 6, 2026 — ICCC rises 2.3% to $9.97
- Closed at $9.97, +2.26% vs the prior close of $9.75. Day range $9.93–$9.97, opened at $9.93.
- Volume was 800 shares, 0.0x its 50-day average of 21.74K — lighter than usual.
- Price is -2.1% vs its 50-day average ($10.19) and +17.4% vs its 200-day average ($8.49).
- 52-week range $4.52–$12.10; today's close sits at 72% of that range, 17.6% below the 52-week high.
Oct 5, 2026 — ICCC ends flat (+0.0%) to $9.75
- Closed at $9.75, +0.00% vs the prior close of $9.75. Day range $9.67–$9.80, opened at $9.75.
- Volume was 11.30K shares, 0.5x its 50-day average of 21.69K — lighter than usual.
- Price is -4.5% vs its 50-day average ($10.21) and +15.1% vs its 200-day average ($8.47).
- 52-week range $4.52–$12.10; today's close sits at 69% of that range, 19.4% below the 52-week high.
Oct 2, 2026 — ICCC rises 1.6% to $9.75
- Closed at $9.75, +1.56% vs the prior close of $9.60. Day range $9.61–$9.80, opened at $9.80.
- Volume was 5.80K shares, 0.3x its 50-day average of 21.96K — lighter than usual.
- Price is -4.7% vs its 50-day average ($10.24) and +15.3% vs its 200-day average ($8.46).
- 52-week range $4.52–$12.10; today's close sits at 69% of that range, 19.4% below the 52-week high.
ICCC latest news & SEC filings
Every SEC filing by or about ICCC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.19M (prior year $6.44M) (+11.5% vs Jun 30, 2025)
- Net income: $1.83M (prior year $501.88K) (+265.6% vs Jun 30, 2025)
- Diluted EPS: $0.20 (prior year $0.06) (+233.3% vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Te Boekhorst Paul Francis Olivier bought 8,000 shares at $9.50 (≈$76.00K) on Jun 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade ICCC
- Last results release: Oct 13, 2026 (8-K Item 2.02). Previous ones: Aug 13, 2026, Jul 9, 2026, May 14, 2026. Based on that rhythm, the next report is likely around Jan 12, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.65% (largest 12.4%).
- Liquidity: about 11.23K shares (≈$118.64K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $10.56 vs a range of $4.52–$12.10 (80% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Boekhorst Paul Francis Olivier Te bought 8,000 shares on Jun 18, 2026.
- Latest filings: 8-K Oct 13, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 9.08M shares outstanding (Jul 31, 2026), +0.4% vs a year earlier.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
ICCC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 10.45 | 10.89 | 10.45 | 10.56 | 9.90K |
| Oct 14, 2026 | 10.80 | 10.80 | 10.50 | 10.75 | 9.40K |
| Oct 13, 2026 | 10.79 | 10.80 | 10.15 | 10.79 | 50.30K |
| Oct 12, 2026 | 9.75 | 9.80 | 9.60 | 9.60 | 11.20K |
| Oct 9, 2026 | 9.75 | 9.80 | 9.65 | 9.80 | 1.90K |
| Oct 8, 2026 | 9.74 | 9.85 | 9.65 | 9.75 | 5.10K |
| Oct 7, 2026 | 9.96 | 9.99 | 9.69 | 9.69 | 5.20K |
| Oct 6, 2026 | 9.93 | 9.97 | 9.93 | 9.97 | 800 |
| Oct 5, 2026 | 9.75 | 9.80 | 9.67 | 9.75 | 11.30K |
| Oct 2, 2026 | 9.80 | 9.80 | 9.61 | 9.75 | 5.80K |
| Oct 1, 2026 | 9.80 | 9.80 | 9.55 | 9.60 | 39.50K |
| Sep 30, 2026 | 9.88 | 9.90 | 9.74 | 9.80 | 2.50K |
| Sep 29, 2026 | 9.92 | 10.10 | 9.92 | 9.94 | 2.90K |
| Sep 28, 2026 | 9.78 | 10.11 | 9.69 | 9.88 | 4.50K |
| Sep 25, 2026 | 9.96 | 9.96 | 9.67 | 9.93 | 5.10K |
| Sep 24, 2026 | 9.96 | 10.08 | 9.96 | 9.97 | 2.10K |
| Sep 23, 2026 | 10.03 | 10.07 | 9.85 | 9.99 | 7.90K |
| Sep 22, 2026 | 10.10 | 10.10 | 9.81 | 9.99 | 36.10K |
| Sep 21, 2026 | 9.80 | 10.16 | 9.74 | 10.13 | 3.20K |
| Sep 18, 2026 | 9.80 | 9.99 | 9.68 | 9.95 | 10.00K |
About Immucell
Immucell (ICCC) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in PORTLAND, ME. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 811641.
ICCC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael F Brigham | Director | Mar 24, 2026 |
| Gloria F Basse | Director | Apr 16, 2026 |
| Bobbi Jo Brockmann | VP of Sales and Marketing | Apr 14, 2026 |
| Anthony Dimarco | Director | Apr 23, 2026 |
| Timothy C Fiori | Chief Financial Officer | Jan 29, 2026 |
| Bryan K. Gathagan | Director | Apr 14, 2026 |
| Gilles Guillemette | Director | Apr 23, 2026 |
| Steven T. Rosgen | Director | Apr 14, 2026 |
| David Scott Tomsche | Director | Apr 16, 2026 |
| Kathy V Turner | Director | Apr 16, 2026 |
| Paul R Wainman | Director | Apr 16, 2026 |
| Boekhorst Paul Francis Olivier Te | President and CEO | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Bobbi Jo Brockmann | VP of Sales and Marketing | Apr 14, 2026 |
| Timothy C Fiori | Chief Financial Officer | Jan 29, 2026 |
| Boekhorst Paul Francis Olivier Te | President and CEO | Jun 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | Boekhorst Paul Francis Olivier Te | Buy | 8,000 | $9.50 |
| Dec 4, 2025 | Boekhorst Paul Francis Olivier Te | Buy | 2,432 | $5.50 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier Te | Buy | 3,598 | $5.05 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier Te | Buy | 2,556 | $5.00 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier Te | Buy | 3,521 | $5.04 |
| Dec 2, 2025 | Boekhorst Paul Francis Olivier Te | Buy | 3,708 | $4.87 |
| Nov 25, 2025 | David Scott Tomsche | Buy | 1,633 | $4.76 |
| Nov 25, 2025 | David Scott Tomsche | Buy | 1,633 | $4.77 |
ICCC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $27.64M | $-1.04M | -0.12 | $2.48M |
| Dec 31, 2024 | $26.49M | $-2.16M | -0.26 | $357.90K |
| Dec 31, 2023 | $17.47M | $-5.77M | -0.75 | $-4.67M |
| Dec 31, 2022 | $18.57M | $-2.49M | -0.32 | $-1.54M |
| Dec 31, 2021 | — | $-78.29K | -0.01 | $954.17K |
Latest balance sheet: total assets $46.63M, total liabilities $15.26M, cash $8.86M (as of Jun 30, 2026).
ICCC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 13, 2026 | 8-K Item 2.02 (results) | $10.79 |
| Aug 13, 2026 | 8-K Item 2.02 (results) | $10.90 |
| Jul 9, 2026 | 8-K Item 2.02 (results) | $11.46 |
| May 14, 2026 | 8-K Item 2.02 (results) | $8.26 |
| Apr 8, 2026 | 8-K Item 2.02 (results) | $6.38 |
| Mar 4, 2026 | 8-K Item 2.02 (results) | $6.46 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $6.57 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $6.05 |
| Oct 7, 2025 | 8-K Item 2.02 (results) | $6.45 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $6.72 |
| Jul 9, 2025 | 8-K Item 2.02 (results) | $6.75 |
| May 14, 2025 | 8-K Item 2.02 (results) | $4.91 |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)Celldex Therapeutics (CLDX)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ICCC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.